Effect of rivaroxaban in radial artery thrombosis

Phase 2

• Conditions: Radial artery thrombosis.; Embolism and thrombosis of arteries of the upper extremities; I74.2

• Registration Number: IRCT20200111046084N1
• Lead Sponsor: Rajaie Cardiovascular Medical and Research Center

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 15 June 2020

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

Provision of signed and dated informed consent form
All the patients that diagnosed with radial artery thrombosis after coronary angiography
Men and Women
being at the age of 18 years old or over

Exclusion Criteria

Patients undergoing percutaneous coronary intervention
A condition associated with a high risk of bleeding
Severe renal dysfunction (creatinine clearance <30 mL/min)
Being allergic to rivaroxaban/enoxaparin

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Radial artery recanalization. Timepoint: 4 weeks after start of treatment with rivaroxaban or enoxaparin. Method of measurement: Doppler Ultrasound.

Secondary Outcome Measures

Name	Time	Method
Bleeding. Timepoint: During 4 weeks of treatment with rivaroxaban or enoxaparin. Method of measurement: Questionnaire.